Literature DB >> 21518255

TEC family kinases in health and disease--loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK.

Alamdar Hussain1, Liang Yu, Rani Faryal, Dara K Mohammad, Abdalla J Mohamed, C I Edvard Smith.   

Abstract

The TEC family is ancient and constitutes the second largest family of cytoplasmic tyrosine kinases. In 1993, loss-of-function mutations in the BTK gene were reported as the cause of X-linked agammaglobulinemia. Of all the existing 90 tyrosine kinases in humans, Bruton's tyrosine kinase (BTK) is the kinase for which most mutations have been identified. These experiments of nature collectively provide a form of mutation scanning with direct implications for the several hundred endogenous signaling proteins carrying domains also found in BTK. In 2009, an inactivating mutation in the ITK gene was shown to cause susceptibility to lethal Epstein-Barr virus infection. Both kinases represent interesting targets for inhibition: in the case of BTK, as an immunosuppressant, whereas there is evidence that the inhibition of inducible T-cell kinase (ITK) could influence the infectivity of HIV and also have anti-inflammatory activity. Since 2006, several patients carrying a fusion protein, originating from a translocation joining genes encoding the kinases ITK and spleen tyrosine kinase (SYK), have been shown to develop T-cell lymphoma. We review these disease processes and also describe the role of the N-terminal pleckstrin homology-Tec homology (PH-TH) domain doublet of BTK and ITK in the downstream intracellular signaling of such fusion proteins.
© 2011 The Authors Journal compilation © 2011 FEBS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21518255     DOI: 10.1111/j.1742-4658.2011.08134.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  16 in total

Review 1.  Tec family kinases Itk and Rlk / Txk in T lymphocytes: cross-regulation of cytokine production and T-cell fates.

Authors:  Julio Gomez-Rodriguez; Zachary J Kraus; Pamela L Schwartzberg
Journal:  FEBS J       Date:  2011-03-29       Impact factor: 5.542

Review 2.  Structure, function, and inhibitor targeting of HIV-1 Nef-effector kinase complexes.

Authors:  Ryan P Staudt; John J Alvarado; Lori A Emert-Sedlak; Haibin Shi; Sherry T Shu; Thomas E Wales; John R Engen; Thomas E Smithgall
Journal:  J Biol Chem       Date:  2020-08-29       Impact factor: 5.157

Review 3.  Gastric adenocarcinoma in the context of X-linked agammaglobulinemia: case report and review of the literature.

Authors:  Aidé Tamara Staines Boone; María Guadalupe Torres Martínez; Gabriela López Herrera; Julia O de Leija Portilla; Sara Elva Espinosa Padilla; Francisco J Espinosa Rosales; Saúl Oswaldo Lugo Reyes
Journal:  J Clin Immunol       Date:  2013-12-12       Impact factor: 8.317

Review 4.  PI3K and STAT3: a new alliance.

Authors:  Peter K Vogt; Jonathan Ross Hart
Journal:  Cancer Discov       Date:  2011-11       Impact factor: 39.397

5.  Signaling of the ITK (interleukin 2-inducible T cell kinase)-SYK (spleen tyrosine kinase) fusion kinase is dependent on adapter SLP-76 and on the adapter function of the kinases SYK and ZAP70.

Authors:  Alamdar Hussain; Dara K Mohammad; Manuela O Gustafsson; Merve Uslu; Abdulrahman Hamasy; Beston F Nore; Abdalla J Mohamed; C I Edvard Smith
Journal:  J Biol Chem       Date:  2013-01-04       Impact factor: 5.157

6.  Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Authors:  Jason A Dubovsky; Kyle A Beckwith; Gayathri Natarajan; Jennifer A Woyach; Samantha Jaglowski; Yiming Zhong; Joshua D Hessler; Ta-Ming Liu; Betty Y Chang; Karilyn M Larkin; Matthew R Stefanovski; Danielle L Chappell; Frank W Frissora; Lisa L Smith; Kelly A Smucker; Joseph M Flynn; Jeffrey A Jones; Leslie A Andritsos; Kami Maddocks; Amy M Lehman; Richard Furman; Jeff Sharman; Anjali Mishra; Michael A Caligiuri; Abhay R Satoskar; Joseph J Buggy; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2013-07-25       Impact factor: 22.113

7.  The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.

Authors:  Girija Dasmahapatra; Hiral Patel; Paul Dent; Richard I Fisher; Jonathan Friedberg; Steven Grant
Journal:  Br J Haematol       Date:  2013-01-30       Impact factor: 6.998

Review 8.  Splice-correction strategies for treatment of X-linked agammaglobulinemia.

Authors:  Burcu Bestas; Janne J Turunen; K Emelie M Blomberg; Qing Wang; Robert Månsson; Samir El Andaloussi; Anna Berglöf; C I Edvard Smith
Journal:  Curr Allergy Asthma Rep       Date:  2015-03       Impact factor: 4.806

Review 9.  Interleukin-2-inducible T-cell kinase (ITK) deficiency - clinical and molecular aspects.

Authors:  Sujal Ghosh; Kirsten Bienemann; Kaan Boztug; Arndt Borkhardt
Journal:  J Clin Immunol       Date:  2014-10-24       Impact factor: 8.317

10.  Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment.

Authors:  Xiaohui Zheng; Ning Ding; Yuqin Song; Lixia Feng; Jun Zhu
Journal:  Cancer Cell Int       Date:  2014-04-03       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.